Johns Hopkins HIV Guide
Entecavir
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis B (HBV) infection in adults and children at least 2 years of age with evidence of active disease (active viral replication, elevated ALT or AST or histologic evidence of active disease).
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 2, 2017
Citation
Smith, Janessa, and Paul A Pham. "Entecavir." Johns Hopkins HIV Guide, 2017. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545066/6/Entecavir.
Smith J, Pham PA. Entecavir. Johns Hopkins HIV Guide. 2017. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545066/6/Entecavir. Accessed December 5, 2023.
Smith, J., & Pham, P. A. (2017). Entecavir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545066/6/Entecavir
Smith J, Pham PA. Entecavir [Internet]. In: Johns Hopkins HIV Guide. ; 2017. [cited 2023 December 05]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545066/6/Entecavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Entecavir
ID - 545066
A1 - Smith,Janessa,Pharm.D. BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2017/10/02/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545066/6/Entecavir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
